Market Cap
$284.0M
FATE
FATE THERAPEUTICS INC
$2.32 ▲ +0.87%
Prev close $2.30Market cap$284.0M
ConsensusBuy
12-mo target$5.74 (+147.6%)
▲ Bullish
Analyst conviction 6/10
Insider Selling Cluster (2 insiders)27 New Institutional Positions16 Institutional Exits Biotech & Drug DiscoveryGenomics & Gene Editing
Snapshot
The big-picture read on FATE right now — valuation, ownership and activity at a glance.
Cap Size
Micro Cap
Analyst Consensus
Buy (61%)
Inst. Holders
50 funds
Inst. Value
$121.9M
Inst. Activity
27 buys / 16 sells
Insider Activity
$0.00 buy / $306.1K sell
Insider Net $
-$306.1K
Social Sentiment
33° Cool
SEC Reports
6
Press Releases
3
Price chart 30d -4.1%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 2, 2026 other
Aug 14, 2026 Press Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stag
Fate Therapeutics announced first patient dosed in the Phase 2 potentially registrational RECLAIM-LN trial of FT819 for
Impact 5/10
Fate Therapeutics reported Q2 2026 results with a net loss of $0.25 per share, slightly beating the consensus estimate o
8-K — Impact 5/10
Two insiders at Fate Therapeutics, including the CEO, sold a combined $204K worth of shares in open-market transactions
CLUSTER — Impact 5/10
Aug 4, 2026 Insider
Valamehr Bahram sold 43,947 shares
President and CEO @ $2.46 ($108.1K)
Aug 4, 2026 Insider
TAHL CINDY sold 38,800 shares
See Remarks @ $2.46 ($95.4K)
Jun 30, 2026 Inst.
BlackRock, Inc. — TRIM
7,298,895 shares ($19.7M)
Jun 30, 2026 Inst.
GOLDMAN SACHS GROUP INC — ADD
2,049,187 shares ($5.5M)
Analyst ratings buy % +0.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
61% rate it Buy or better · 18 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Aug 14, 2026 | Piper Sandler | REITERATE | Overweight | 54% |
| Aug 14, 2026 | Wells Fargo | MAINTAIN | Equal-Weight | 54% |
| Aug 14, 2026 | Wedbush | REITERATE | Outperform | 57% |
| Jun 8, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| May 4, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | 43% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 5 | 6 | 7 | 0 | 0 | 61% | |
| Aug 1, 2026 | 5 | 6 | 7 | 0 | 0 | 61% | |
| Jul 1, 2026 | 5 | 6 | 7 | 0 | 0 | 61% | |
| Jun 1, 2026 | 5 | 6 | 7 | 0 | 0 | 61% | |
| May 1, 2026 | 5 | 6 | 7 | 0 | 0 | 61% | |
| Apr 1, 2026 | 5 | 6 | 7 | 0 | 0 | 61% | |
| Mar 1, 2026 | 5 | 6 | 7 | 0 | 0 | 61% | |
| Feb 1, 2026 | 5 | 6 | 7 | 0 | 0 | 61% |
Price targets
Where 9 covering analysts think FATE trades over the next 12 months.
$5.74 +147.6% upside Strong Buy
Current$2.32 Low$2.20 Median$7.00 High$8.00 9 analysts
$2.20$8.00
Analyst rating Buy· 2.2/5 as of Oct 2, 2026
Social media sentiment mood +0.0%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
33°
Cool
BearishNeutralBullish
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
6 SEC filing reports analyzed · 0 bullish, 2 bearish, 0 mixed, 4 neutral · avg impact 4.5/10.Plus 3 press releases.
NEUTRAL8-K5/10
Fate Therapeutics reported Q2 2026 results with a net loss of $0.25 per share, slightly beating the
Aug 13, 2026
BEARISHCLUSTER5/10
Two insiders at Fate Therapeutics, including the CEO, sold a combined $204K worth of shares in open-
Aug 6, 2026
BEARISHINST-CLUSTER5/10
FATE Therapeutics saw a bearish institutional cluster in Q3 2025, with 5 sellers (including Citadel
Jun 11, 2026
NEUTRAL8-K4/10
Fate Therapeutics filed an 8-K on June 4, 2026, to update its corporate presentation for the EULAR 2
Jun 4, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Oct 2, 2026
other
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing
Oct 1, 2026
earnings
Fate Therapeutics to Participate in Upcoming Fourth Quarter 2026 Conferences
SAN DIEGO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing
Sep 29, 2026
short_volume
Short Volume: FATE — 63.7% short (0.3M / 0.5M)
Short: 324,575 | Exempt: 456 | TRF Vol: 509,427 | Short Ratio: 63.7% | Off-exchange volume (dark pool + OTC)
Sep 25, 2026
other
Fate Therapeutics Announces Receipt of California Institute for Regenerative Medicine (CIRM) CLIN2 Grant to Advance RECLAIM-LN
$15.0 Million Award to Support Advancement of RECLAIM-LN, a Phase 2 Potentially Registrational Trial of FT819 Off-the-Shelf CAR T-Cell Therapy in Lupu
Sep 25, 2026
short_volume
Short Volume: FATE — 83.4% short (1.3M / 1.5M)
Short: 1,276,462 | Exempt: 290 | TRF Vol: 1,530,802 | Short Ratio: 83.4% | Off-exchange volume (dark pool + OTC)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.26 | $-0.28–$-0.21 | 5.6% | +0.0% | 4↑ 2↓ | $0.0B | 8 |
| Next Q | $-0.27 | $-0.34–$-0.22 | 0.0% | +0.0% | 3↑ 3↓ | $0.0B | 8 |
| Current FY | $-1.02 | $-1.11–$-0.88 | 11.5% | +0.0% | 4↑ 2↓ | $0.0B | 8 |
| Next FY | $-0.97 | $-1.30–$-0.64 | 4.9% | +0.0% | 3↑ 1↓ | $0.0B | 8 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.255 | — |
| 7d ago | $-0.255 | — |
| 30d ago | $-0.255 | — |
| 60d ago | $-0.262 | +0.007 |
| 90d ago | $-0.262 | +0.007 |
Institutional ownership
Which big funds own FATE (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $121.9M total value (45,191,513 shares) as of 2026-Q2. Top holders: BlackRock,, VANGUARD, VANGUARD. Net buying activity: 27 institutions added/increased vs 16 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| BlackRock, Inc. | 7,298,895 | $19.7M | 16.2% | TRIM -27.5% |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 4,545,893 | $12.3M | 10.1% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 4,445,536 | $12.0M | 9.8% | — |
| AQR CAPITAL MANAGEMENT LLC | 3,837,229 | $10.4M | 8.5% | DOUBLED +158.3% |
| TWO SIGMA INVESTMENTS, LP | 3,589,863 | $9.7M | 7.9% | — |
| RENAISSANCE TECHNOLOGIES LLC | 2,983,268 | $8.1M | 6.6% | ADD +26.0% |
| MILLENNIUM MANAGEMENT LLC | 2,433,978 | $6.6M | 5.4% | — |
| GOLDMAN SACHS GROUP INC | 2,049,187 | $5.5M | 4.5% | ADD +54.3% |
| GEODE CAPITAL MANAGEMENT, LLC | 1,322,013 | $3.6M | 2.9% | TRIM -49.0% |
| JANE STREET GROUP, LLC | 1,027,007 | $2.8M | 2.3% | ADD +58.7% |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| BlackRock, Inc. | TRIM | 10,068,614 | 7,298,895 | -27.5% | $19.7M |
| GOLDMAN SACHS GROUP INC | ADD | 1,327,757 | 2,049,187 | +54.3% | $5.5M |
| GEODE CAPITAL MANAGEMENT, LLC | TRIM | 2,590,429 | 1,322,013 | -49.0% | $3.6M |
| JANE STREET GROUP, LLC | ADD | 646,979 | 1,027,007 | +58.7% | $2.8M |
| UBS Group AG | TRIM | 1,821,715 | 590,178 | -67.6% | $1.6M |
| STATE STREET CORP | NEAR_EXIT | 2,263,173 | 558,928 | -75.3% | $1.5M |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | ADD | 298,496 | 511,050 | +71.2% | $1.4M |
| IEQ CAPITAL, LLC | ADD | 324,788 | 487,728 | +50.2% | $1.3M |
| Point72 Asset Management, L.P. | DOUBLED | 43,119 | 442,228 | +925.6% | $1.2M |
| DIMENSIONAL FUND ADVISORS LP | TRIM | 883,790 | 352,226 | -60.1% | $949.1K |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
11 insiders, 22 transactions. Net -$306.1K — $0.00 bought, $306.1K sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Aug 4, 2026 | Valamehr Bahram | President and CEO | SELL | 43,947 | $2.46 | $108.1K |
| Aug 4, 2026 | TAHL CINDY | See Remarks | SELL | 38,800 | $2.46 | $95.4K |
| Jun 12, 2026 | Redmile Group, LLC | Director | AWARD | 87,900 | — | — |
| Jun 12, 2026 | Lee Michael Stewart | Director | AWARD | 87,900 | — | — |
| Jun 12, 2026 | Hamill Laura | Director | AWARD | 175,800 | — | — |
| Jun 12, 2026 | ABERNETHY MATT | Director | AWARD | 87,900 | — | — |
| Jun 12, 2026 | RASTETTER WILLIAM H | Director | AWARD | 87,900 | — | — |
| Jun 12, 2026 | Agarwal Shefali | Director | AWARD | 87,900 | — | — |
| Jun 12, 2026 | EPSTEIN ROBERT S | Director | AWARD | 87,900 | — | — |
| Jun 12, 2026 | Xu Yuan | Director | AWARD | 87,900 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for FATE.
Shares short
9,386,451
Settlement Sep 15, 2026
Change vs prior
+3.0%
Semi-monthly cycle
Days to cover
10.5
At avg daily volume
Of shares outstanding
≈7.8%
Estimate — not % of float
All FATE filing & press-release reports (9)
- PRESS-RELEASE reportAug 14, 2026
- 8-K reportAug 13, 2026
- CLUSTER reportAug 6, 2026
- INST-CLUSTER reportJun 11, 2026
- 8-K reportJun 4, 2026
- PRESS-RELEASE reportJun 1, 2026
- 8-K reportMay 13, 2026
- PRESS-RELEASE reportMay 11, 2026
- DEFA14A reportApr 24, 2026